Skip to navigation Skip to content

Psoriasis (PSOR) Program in Pharmaceutical Benefits Scheme (PBS) 012-18051130

Expand/Collapse all sectionsExpand all


This document outlines details of PBS-subsidised biological medicines for patients with severe chronic plaque psoriasis (PSOR).

For information on how to process a PBS Authority, see Processing Complex Authority Required Listings.

On this page:

Psoriasis (PSOR) adult quick reference

Psoriasis (PSOR) paediatric quick reference

Contraindication to prior therapy

Delayed assessment

Psoriasis (PSOR) adult quick reference

Table 1

Restrictions

Authority level and section

PA assessment

Processing system

Prescriber type

Prescriber self-serve

Initial

PB112 form

Written

Electronic

S85:

adalimumab

bimekizumab

etanercept

guselkumab

infliximab s.c.

ixekizumab

risankizumab

secukinumab

tildrakizumab

ustekinumab

S100:

infliximab i.v.

No

OPA

Must be treated by a:

  • dermatologist

Yes - delayed assessment (due to PASI assessment attachment and any free text option used)

Change (<5 years)

or

recommencement (<5 years)

PB263 form

Written

Electronic

S85:

adalimumab

bimekizumab

etanercept

guselkumab

infliximab s.c.

ixekizumab

risankizumab

secukinumab

tildrakizumab

ustekinumab

S100:

infliximab i.v.

No

OPA

Must be treated by a:

  • dermatologist

Yes - immediate or delayed assessment (delayed if any free text option used)

Recommencement (>5 years)

PB263 form

Written

Electronic

S85:

adalimumab

bimekizumab

etanercept

guselkumab

infliximab s.c.

ixekizumab

risankizumab

secukinumab

tildrakizumab

ustekinumab

S100:

infliximab i.v.

No

OPA

Must be treated by a:

  • dermatologist

Yes

First continuing

PB113 form

Written

Electronic

S85:

adalimumab

bimekizumab

etanercept

guselkumab

infliximab s.c.

ixekizumab

risankizumab

secukinumab

tildrakizumab

ustekinumab

S100:

infliximab i.v.

No

OPA

Must be treated by a:

  • dermatologist

Yes

Subsequent continuing

PB113 form

Written

Electronic

S85:

adalimumab

bimekizumab

etanercept

guselkumab

infliximab s.c.

ixekizumab

risankizumab

secukinumab

tildrakizumab

ustekinumab

S100:

infliximab i.v.

No

OPA

Must be treated by a:

  • dermatologist

Yes

Subsequent continuing - biosimilar brand

Streamlined

S85:

adalimumab

etanercept

ustekinumab

S100:

infliximab i.v.

(Telephone for increased quantities of infliximab i.v. for patients>100kg)

No

N/A

Must be treated by a:

  • dermatologist

N/A

Balance of supply

(top -up)

Telephone

Electronic

S85:

adalimumab

bimekizumab

etanercept

guselkumab

infliximab s.c.

ixekizumab

risankizumab

secukinumab

tildrakizumab

ustekinumab

S100:

infliximab i.v.

No

OPA

Must be treated by a:

  • dermatologist

Yes

Psoriasis (PSOR) paediatric quick reference

Table 2: etanercept

Restrictions

Authority level and section

PA assessment

Processing system

Prescriber type

Prescriber self-serve

Initial

Telephone

Electronic

S85:

etanercept

No

OPA

Must be treated by a:

  • dermatologist

Yes

Change

Telephone

Electronic

S85:

etanercept

No

OPA

Must be treated by a:

  • dermatologist

Yes

Recommencement

Telephone

Electronic

S85:

etanercept

No

OPA

Must be treated by a:

  • dermatologist

Yes

Re-treatment

Telephone

Electronic

S85:

etanercept

No

OPA

Must be treated by a:

  • dermatologist

Yes

Balance of supply

(top-up)

Telephone

Electronic

S85:

etanercept

No

OPA

Must be treated by a:

  • dermatologist

Yes

Completion of course

Streamlined

S85:

etanercept

No

N/A

Must be treated by a:

  • dermatologist

N/A

Table 3: adalimumab and ustekinumab

Restrictions

Authority level and section

PA assessment

Processing system

Prescriber type

Prescriber self-serve

Initial

PB320 form

Written

Electronic

S85:

adalimumab

ustekinumab

No

OPA

Must be treated by a:

  • dermatologist

Yes - immediate or delayed assessment (delayed due to any free text option used)

Change

or

recommencement

PB320 form

Written

Electronic

S85:

adalimumab

ustekinumab

No

OPA

Must be treated by a:

  • dermatologist

Yes

First continuing

PB319 form

Written

Electronic

S85:

adalimumab

ustekinumab

No

OPA

Must be treated by a:

  • dermatologist

Yes

Subsequent continuing - all brands

Streamlined

S85:

adalimumab

No

N/A

Must be treated by a:

  • dermatologist

N/A

Subsequent continuing - originator

PB319 form

Written

Electronic

S85:

ustekinumab

No

OPA

Must be treated by a:

  • dermatologist

Yes

Subsequent continuing - biosimilar

Streamlined

S85:

ustekinumab

No

N/A

Must be treated by a:

  • dermatologist

N/A

Balance of supply

Telephone

Electronic

S85:

adalimumab

Ustekinumab

No

OPA

Must be treated by a:

  • dermatologist

Yes

Contraindication to prior therapy

Table 4: this table lists the details of contraindication to each prior systemic therapy according to the relevant Therapeutic Goods Administration (TGA) approved Product Information.

Escalate to a Pharmaceutical Adviser (PA) if unsure about the contraindication to phototherapy.

Prior therapy

Contraindication

methotrexate
  • Hypersensitivity
  • Pregnancy
  • Breastfeeding
  • Severe hepatic impairment
  • Severe renal impairment
  • Alcoholism or alcoholic liver disease
  • Overt or laboratory evidence of immunodeficiency syndromes
  • Bone marrow depression or pre-existing blood dyscrasias, such as bone marrow hypoplasia, leucopenia, thrombocytopenia or anaemia
  • Serious, acute or chronic infections
  • Peptic ulcer disease or ulcerative colitis
  • Concurrent vaccinations with live vaccines
  • Concomitant administration with retinoids such as acitretin

ciclosporin
  • Hypersensitivity
  • Uncontrolled hypertension
  • Uncontrolled infection
  • Primary or secondary immunodeficiency (excluding autoimmune diseases and selective IgA deficiency)
  • Impaired renal function

acitretin
  • Pregnancy
  • Women of childbearing potential
  • Hypersensitivity to acitretin or other retinoids
  • Breastfeeding
  • Severely impaired liver or kidney function
  • Chronic abnormally elevated blood lipid values
  • Combined use with tetracycline
  • Combined use with methotrexate
  • Concomitant administration with vitamin A or other retinoids

apremilast
  • Hypersensitivity
  • Pregnancy
  • Breastfeeding

deucravacitinib
  • Hypersensitivity

Delayed assessment

Table 5: this table lists the details of what to check for the delayed assessment due to intolerance to prior therapy and common acronyms used.

Service Officers to assess that free text is:

Examples

Outcome

Relevant to the question

  • Hypersensitivity to any components of the formulation
  • Gastrointestinal adverse reactions
  • Nausea and vomiting
  • LFT derangement

Approve

Random text
  • Happy Birthday
  • Patient did not want to take
  • Ikasditbn

Reject

Non-descriptive
  • Toxicity (no details)
  • Ineffective
  • Intolerance

Reject

Common acronyms

  • LFT - Liver function tests
  • GI toxicity - Gastrointestinal
  • N+V - Nausea and vomiting

Escalate to a Pharmaceutical Adviser (PA) by phone if unsure of the acronym used.